Zacks upgraded shares of PharMerica Corp. (NYSE:PMC) from a neutral rating to an outperform rating in a research report released on Monday morning, Analyst Ratings News reports. Zacks currently has $27.20 price objective on the stock. Zacks has also modified their ratings on a number of other healthcare stocks in the few days. The firm […]
PharMerica Corp. Stock Rating Upgraded by Zacks (PMC) is a post from: Zolmax
The post PharMerica Corp. Stock Rating Upgraded by Zacks (PMC) appeared first on Zolmax.